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Abstract
Background: The objective of this study was to evaluate the carriage of Neisseria meningitidis (Nm) serogroups X
and Y in the health district of Kaya before the introduction of a serogroup A meningococcal conjugate vaccine in
Burkina Faso.
Methods: A repeated cross-sectional meningococcal carriage study was conducted in 2009 in eight randomly
selected villages in the health district of Kaya, Burkina Faso. In each of 4 sampling rounds at least 1,500 people were
enrolled within a 1-month period.
Results: From a total of 6,686 throat swabs we identified 419 Nm isolates (6.27%). The dominating serogroups were
Y (3.19%) and X (1.05%). Overall carriage was higher in the dry season compared with the rainy season (OR, 1.51;
95% CI, 1.06–2.16). Carriage prevalence of serogroups Y and X varied by round and was highest at the end of the
dry season (4.92% and 1.22%, respectively). The only risk factor associated with NmX carriage was vaccination status
in contrast to serogroup Y, which was associated with age groups 5–9 years and 10–14 years.
Conclusion: The presence of Nm serogroups X and Y, which could replace or be added to the serogroup A, is a
warning sign. There is a need to strengthen surveillance and laboratory diagnosis of the various meningococcal
serogroups circulating in Africa.
Keywords: Meningococcal meningitis, Serogroups X and Y, Carriage, Risk factor
Background
Meningococcal meningitis is a major public health prob-
lem globally [1]. According to the World Health
Organization (WHO), the number of cases of meningitis
over the last 15 years is estimated to be more than 700,000,
with a fatality rate of over 10% and sequelae reported in
more than 20% of surviving patients [1]. Overall, about
500,000 cases of meningococcal disease occur each year
causing at least 50,000 deaths. Meningococcal meningitis
has a case-fatality rate of 5%–10% in industrialized countries,
which can reach 20% in the developing world. In addition,
12%–19% of survivors develop long-term neurological
sequelae [2,3]. Sub-Saharan Africa, and in particular the
area known as the Lapeyssonnie meningitis belt, is the most
affected region. This area, with a population estimated at
about 500 million inhabitants, stretches from Senegal to
Ethiopia [1,4]. In countries located in this area, there is an
upsurge in cases of meningitis in the dry season every year,
which gives a high endemic background [1,5,6]. This men-
ingitis is mostly caused by meningococcal serogroup A.
In Burkina Faso, 78,518 cases of meningitis with 8,568
deaths were recorded between 2003 and 2009, a lethality
rate of 11%. Nearly 65% of cases were due to Neisseria
meningitidis serogroup A. The latest epidemic year was
2007, with 26,878 recorded cases and 1,923 deaths. In
2008, 10,401 cases and1,067 deaths were recorded, and
there were 4,723 cases and 629 deaths in 2009 (MDSC
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Meningitis Weekly Bulletin, http://www.who.int/csr/dis-
ease/meningococcal). Moreover, Burkina Faso was the
first country to experience a major serogroup W out-
break in 2002 [7-9], with 13,000 reported cases, of whom
1,400 died (www.who.int/csr/disease/meningococcal/w135).
However, 6960 cases with 63% of serogroup W were re-
ported in 2012.
N. meningitidis colonizes 8%–25% of healthy individuals,
this carriage rate in the oropharynx can be 5%–10% in non-
epidemic periods [10-12]. In 1998, a carriage study examin-
ing nasopharyngeal specimens from 1,818 high school stu-
dents from hypersporadic counties in the metropolitan area
of Atlanta, GA, found the rate of carriage to be 7.7%. Of
these, 48% were serogroup Y [13]. However, in 2006–2007,
a similar carriage study in high school students found a
much lower proportion of serogroup Y carriage [13].
Serogroup X (ST-181) has caused localized outbreaks in
certain African countries, including Kenya, Niger, and Ghana
but is rarely seen as a cause of disease outside of Africa
[14,15]. A study conducted by Kristiansen et al. in Burkina
Faso before the introduction of serogroup A meningococcal
conjugate vaccine showed a carriage rate of serogroup Y
(2.28%) and that of serogroup X (0.44%) [16]. According to
Ministry of Health reports in 2011 and 2012, 11,009 cases of
meningitis were notified with 1,388 deaths. No case of
Neisseria meningitidis serogroup A was observed.
Until 2010 the fight against meningitis was based
primarily on halting ongoing epidemics through reactive
vaccination with bivalent (AC), trivalent (ACY) and tetrava-
lent (ACYW) polysaccharide vaccines [17].
These vaccines containing capsular polysaccharides
have proved safe and effective. However, the immune
protection is short and immunity in children is consid-
ered sub-optimal. Conjugated vaccines, which bind the
polysaccharides to a protein support, induce a stronger
immune response in children less than 2 years of age
and give a longer protection than polysaccharide vaccines
[6,17,18]. According to the WHO Regional Office for Africa
based in Burkina Faso, 153.5 million people were immu-
nized with the serogroup A meningococcal conjugate
vaccine MenAfriVac from 2010 to 2013 in 12 countries
(Burkina Faso, Mali, Niger, Nigeria, Cameroon, Chad,
Sudan, Ethiopia, Benin, Ghana, Senegal, Gambia). Accord-
ing to the same source, 100 million people should receive
the vaccine between 2014 and 2016.
Burkina Faso was the first country to vaccinate the whole
population between 1 and 29 years of age with the
serogroup A meningococcal conjugate vaccine MenAfriVac
[19,20].
A study of meningococcal carriage was conducted from
2009 to 2011 before and after the introduction of the con-
jugate vaccine, which showed that serogroup A carriage
was eliminated for up to 1 year after mass vaccination,
among both vaccinated and non-vaccinated populations
[19]. The results published from this study has not yet
included sub-analysis of evolution and risk factors for
carriage.
The aim of our study was to examine the evolution and
risk factors of X and Y meningococcal carriage in the
period before vaccination in the health district of Kaya,
which is one of the three study sites of the carriage study
conducted in Burkina Faso [16]. This site was studied in
particular because of higher carriage prevalence of
serogroups X and Y compared with the other two study
sites, and because these serogroups had not caused any
outbreak in the past in Burkina Faso.
Methods
Ethics
The study received approval from the Ethics Committee for
Health Research in Burkina Faso, the Norwegian Regional
Committee for Medical Research Ethics, Southern Norway
and the internal Review Board at the Centers for Disease
Control and Prevention (CDC) in Atlanta, GA, USA.
Informed consent was obtained from all study participants.
The study site
This is a repeated cross-sectional study with four sampling
rounds of 1 month each, which took place from 26 January
2009 to 06 December 2009 in the health district of Kaya,
Burkina Faso. The health district of Kaya is located in the
northeast of Burkina Faso and the capital of the province is
about 100 km from Ouagadougou, the capital of the
country. Within the district, eight villages were selected by
probability proportional to size. They included: Tamdogo,
Terrin Mossi, Forgui, Boulsin, Mastenga, Iryastenga, Foulla
and Noungou. In each round, at least 1,500 people meeting
the criteria for participation in the study were enrolled.
Sampling method
In each of the selected villages, all compounds were
mapped with the use of a global positioning system (GPS)
before the study started. For each round and in each
village, 30 compounds were randomly selected using the
GPS coordinates.
Inclusion of participants and administration of
questionnaires
The village population was informed about the project
through local health workers and community leaders. Each
randomly selected compound was visited by study personnel
and the purpose of the study was explained. A first question-
naire with general questions about the compound was
administered to the head of the compound after his written
consent was obtained. The first questionnaire included the
following information: number of people living in the house-
hold; number of rooms in the household; whether toilets
and bathrooms were present; how many people usually slept
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in the same room; how many people usually slept on the
same surface (e.g., bed, mattress); how many people in the
household had been affected by meningitis in the last
5 years; and type of fuel used. Then, a second question-
naire was administered for each of the 1- to 29-year-old
members of the household, who presented no signs of
chronic illness or obvious malnutrition, and lived at the
household. Individual written consent or, in the case of
children below 18 years of age, the consent of their parent
or guardian was first obtained. Each participant was given
a paper wristband with a barcode corresponding to a
unique identifier number linked to the questionnaire. The
second questionnaire queried the following: sex; age;
whether respondents had been vaccinated against menin-
gitis in the last 5 years; whether medications had been
taken during the last 30 days; whether respondents had
been in a place where they talked with several people
outside work or school in the past month (e.g., wedding,
funeral, market); whether they had made a pilgrimage to
the Hajj; occupation (for those 12 years old or older);
attendance at school and type of school (for 5- to 19-year-
old respondents); and tobacco use (for those 10 years old
or older). For children below 18 years the answers were
completed by their parent or guardian if necessary.
Sample collection and analysis
Oropharyngeal samples were obtained by sweeping the pos-
terior pharyngeal wall behind the uvula and one tonsil with
a sterile cotton swab (Copan, Italy) as previously described
[16]. The swab was immediately plated onto modified
Thayer-Martin VCNT agar, containing 3 mg/liter vanco-
mycin, 7.5 mg/liter colistin, 12.5 U/liter nystatin, 5 mg/liter
trimethoprim lactate, and Vitox supplement (produced by
the WHO Multi-Disease Surveillance Centre, Burkina Faso).
In the field, inoculated plates were rapidly incubated in
humidified, CO2-rich air using 7.0-liter jars (Remel, GA)
with a CO2-generating system (CO2 GEN; Oxoid, UK).
Personal digital assistants were used to register the barcode
on the participant’s wristband as well as the barcode label
used on the inoculated plate. This created a link between
the person identifier number and the laboratory specimen
number. The jars with the plates were incubated at 37°C in
the laboratory within 6 h after sampling. Between 100 and
110 samples were collected daily, 4 days per week, during
the 4 weeks of each campaign [16].
Laboratory analysis
The inoculated agar plates were incubated at 37°C with C02
generators for 24 to 48 hours. Colonies suspected to be
Nm were subcultured on blood agar and incubated at 37°C
under C02. Suspect colonies on fresh blood agar were
tested for oxidase activity, Gram staining, β-galactosidase
(ONPG) activity and γ-glutamyltransferase (GGT) activity
as described [16]. The serogroup was determined by slide
agglutination with capsule-specific antiserum (Remel, GA).
Purified isolates were inoculated into two cryovials contain-
ing 0.5− 1 ml Greaves solution [21] and stored at −70°C.
After each round, one of the vials was sent to the Norwegian
Institute of Public Health (NIPH), Oslo, Norway, on dry ice
for confirmation and further analyses. The final laboratory
results are based on results from NIPH.
Statistical analysis
Descriptive analysis of the data was performed; frequency
tables for the variables of interest were made for each
round. Then, we studied the factors associated with
carriage of NmY and NmX using logistic regression with
survey methods accounting for the cluster sampling
design in STATA v.12.
Results
Description of the sample
A total of 6,686 people, of whom 3,730 (55.8%) were fe-
males, were included in the study during the 4 rounds.
More than half of the participants (55.6%) were less
than 10 years old. Of the 5- to 19-year-old participants,
31.28% attended school. Approximately 70% of respon-
dents had been vaccinated with meningococcal polysac-
charide vaccine. The characteristics of the sample are
given in Table 1.
Table 1 Characteristics of the sample
Characteristics Number Percentage (%)
Age (years)
1–4 1630 24.38
5–9 2088 31.23
10–14 1504 22.49
15 and older 1464 21.90
Total 6686 100
Schooling
Yes 1358 31.28
No 2984 68.72
Total 4342 100
Vaccination
Yes 4579 68.49
No 2032 30.39
Don’t know 75 1.12
Total 6686 100
Medication
Yes 2452 36.67
No 4234 63.33
Total 6686 100
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Meningococcal carriage prevalence
Overall meningococcal carriage in Kaya was 6.27% with a
higher prevalence in the dry season (6.03% in round 1 and
8.83% in round 2) compared with the rainy season (5.43%
in round 3 and 4.71% in round 4) (odds ratio (OR) dry
season: rainy season, 1.51; 95% confidence interval (CI),
1.06–2.16). Overall, carriage of Nm Y was three times
higher than that of Nm X. Carriage prevalence varied by
round from 0.30% to 1.99% for NmX and from 2.44% to
4.62% for NmY (Table 2). Carriage of other serogroups
was lower; 0.92% (range, 0.61–1.35%) for NmA, 0.53%
(range, 0.35–0.84%) for NmW and 0.58% (range, 0.30–
0.90%) for non-serogroupable Nm.
Risk factors for carriage
The only risk factor associated with NmX carriage was
vaccination status (Table 3). Participants who reported
having received a meningococcal polysaccharide vaccine in
the past 5 years had higher NmX carriage prevalence than
the non-vaccinated population (P = 0.046). No association
with gender, medications or level of education was found.
However, the carriage of Nm Y appears to have a link with
age unlike the X Nm (Tables 3 and 4).
Discussion
Our study, which was conducted over a period of about
1 year concluded that the overall carriage rate of NmY
was three times higher than that of NmX.
In our study the age groups of 5–9 years and 10–14 years
accounted for 31.2% and 22.5% of the participants, which
indicates a wide participation of these age groups in a rural
site like Kaya. Indeed, when they are not attending school,
the children are at home with no particular occupation. We
also found that in these age groups, children cooperated
more often during the oropharyngeal swabbing compared
with those younger than 5 years.
In this study we noticed an increase of the serogroup X
carriage from 0.30% in January–February 2009 (round 1)
to 1.99% in April–May 2009 (round 2). This period, which
corresponds to the dry season, is the period during which
peaks of meningococcal disease are usually recorded [10].
NmX carriage then declined but was still high during
August–September 2009 (round 3) in the rainy season,
the period during which the meningitis disease incidence
is generally low. The climate may be directly linked to in-
creased carriage and epidemic meningococcal meningitis,
but also indirectly linked by influencing communities to
Table 2 Evolution of the carriage prevalence of Neisseria
meningitidis serogroups X and Y in Kaya (Burkina Faso)
by rounds
Round Number of
participants
Nm X Nm Y
Number of
carriers (%)
Number of
carriers (%)
1 1658 5 (0.30%) 49 (2.96%)
2 1710 34 (1.99%) 79 (4.62%)
3 1639 20 (1.22%) 40 (2.44%)
4 1679 11 (0.66%) 45 (2.68%)
Total 6686 70 (1.05%) 213 (3.19%)
Table 3 Risk factors for the carriage of Neisseria
meningitidis serogroup X
Variables Numbers Positive % OR (IC.95) Value of P
Sex
Female 3730 0.97 1
Male 2956 1.15 1.19 [0.78–1.83] 0.359
Age
1–4 1630 1.04 1
5–9 2088 1.15 0.74 [0.56–2.16] 0.739
10–14 1504 1.06 0.93 [0.60–1.73] 0.931
15 and older 1464 0.89 0.63 [0.39–1.84] 0.634
Medication
Yes 2452 1.20 1
No 4234 0.77 1.56 [0.81–3.03] 0.156
Schooling
Yes 1358 0.81 1
No 2984 1.11 1.37 [0.34–5.53] 0.611
Vaccination
No 2032 0.64 1
Yes 4579 1.24 1.96 [1.01–3.78] 0.046
Table 4 Risk factors for the carriage of Neisseria
meningitidis serogroup Y
Variables Numbers Positive % OR [95% CI] Value of P
Sex
Female 3730 2.92 1
Male 2956 3.52 1.21 [0.98–1.50] 0.070
Age
1–4 1630 1.78 1
5–9 2088 3.64 2.09 [1.39–3.14] 0.004
10–14 1504 3.79 2.17 [1.03–4.59] 0.043
15 and older 1464 3.48 1.99 [1.26–3.13] 0.009
Medication
Yes 2452 2.94 1
No 4234 3.33 1.14 [0.78–1.67] 0.445
Schooling
Yes 1358 3.17 1
No 2984 3.95 1.26 [0.92–1.73] 0.128
Vaccination
No 2032 3.10 1
Yes 4579 3.25 1.05 [0.74–1.49] 0.747
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settle down [10,22]. The increase in NmX carriage may be
explained by the proximity of the health district of Kaya to
Niger, which experienced a large outbreak of serogroup X
meningitis in 2006 [23]. In fact, the health district of Kaya
experienced an outbreak of serogroup X meningitis during
the 2010–2011 epidemic season.
The low carriage prevalence of non-serogroupable Nm
reflects the differences in epidemiology of carriage between
and within countries. In Europe one would expect 50% of
the carriage isolates to be non-groupable. Within Burkina
Faso, the proportion of non-groupable Nm was significantly
higher in urban Bogodogo compared to rural sites and most
of non-groupable isolates were assigned to sequence types
known to lack the gene coding for capsule synthesis [16].
The identification of vaccination status as a risk factor
for NmX carriage is disputable because this finding is
dependent on correct reporting (recall bias) and because
we did not control vaccination cards. Furthermore, menin-
gococcal polysaccharide vaccines have previously shown a
questionable impact on pharyngeal carriage, and serogroup
X has not yet been included in any licensed vaccine. In
Burkina Faso, polysaccharide vaccines are only used for mass
vaccination in outbreak situations and the Ministry of Health
confirmed that mass vaccination had been conducted in
Kaya in the past 5 years. Although vaccinated people would
not be able to acquire immunity against NmX, background
immunity in both vaccinated and non-vaccinated people
would be the same so we cannot argue that vaccination is a
clinically significant risk factor for NmX carriage.
The only risk factor associated with NmY carriage preva-
lence was age; we found a statistically significant difference
between age groups. Carriage prevalence was highest in the
age group of 10–14 years followed by the 5–9 year-old age
group. Our study is comparable to that conducted in
Canada in 2003 [24] as well as the one carried out in Mali
in 1970 that found a statistical link between carrying
serogroup A meningococci and the age group of 5–9 years
[25]. In addition the results of a study in Colombia
between 1994 and 2006 showed that over 50% of cases of
meningococcal serogroup Y were young people under 20
[26]. Serogroup Y was the dominant carriage serogroup in
the district of Kaya and this might explain why we found a
significant variation in carriage by age for serogroup Y and
not for X [16].
In our study the use of medicines did not affect X or Y
meningococcal carriage. People gathering at schools, mar-
kets, and public places promotes airborne transmission of
meningococci, but curiously, attending school was not
associated with higher X or Y meningococcal carriage.
Conclusion
Neisseria meningitidis serogroups X and Y circulated
among healthy carriers in the district of Kaya during a
1-year period before the introduction of a serogroup A
conjugate vaccine. Carriage prevalence of both serogroups
increased during the 2009 epidemic season. Round 2, held
from April to May 2009 showed high carriage rates for the
two serogroups. Because countries neighboring Burkina
Faso such as Niger and Ghana have recently experienced
the circulation and epidemic outbreak of serogroup X
meningitis [23,27], the presence in our study of NmX is
alarming as new serogroups with epidemic potential could
replace or be added to serogroup A. This underlines the
need to strengthen surveillance and laboratory diagnosis
in Africa to detect all serogroups of meningococci. This
preliminary study should promote further evaluation of
the role of vaccination on the carriage of meningococci. A
decrease in the carriage through vaccination with a conju-
gate vaccine could help reduce outbreaks of epidemics of
meningitis in the meningitis belt.
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